Incorporating Checkpoint Inhibitor Therapy Into the Management of Head and Neck Squamous Cell Carcinoma

Emerging clinical data and expert guidance on checkpoint inhibitors and other treatment options for head and neck squamous cell carcinoma.
Barbara Burtness, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.99 MB
Released: September 3, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Merck & Co., Inc.

Related Content

From Clinical Care Options, Zofia Piotrowska, MD, MHS, and Stephen V. Liu, MD, review key data from studies of lung cancer treatment presented at ASCO 2020

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 25, 2020 Expired: September 24, 2021

Gain key clinical insights fast, with this short slideset from CCO on lung cancer data presented at 2020 ASCO

Stephen V. Liu, MD Zofia Piotrowska, MD, MHS Released: September 25, 2020

From Clinical Care Options (CCO), expert commentary by Dr Richard Finn on the use of atezolizumab plus bevacizumab for advanced HCC

Richard Finn, MD Released: September 15, 2020

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC

person default Lipika Goyal Goyal, MD, MPhil Amit G. Singal, MD, MS Released: September 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue